Glenmark's Angina treatment drug gets approval from USFDA
- IBEF
- July 10, 2019
Glenmark Pharmaceuticals received final approval from USFDA for its Ranolazine extended-release tablets used for treatment of chronic angina.
The approval has been given for Ranolazine extended release tablets in strengths of 500mg and 1,000mg. The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths
As per the sales data of the 12-month period which ended in May 2019, Ranexa extended-release tablets, 500 mg and 1,000 mg market achieved annual sales of around US$ 929 million, Glenmark said.
The company's current range consists of 158 products authorised for distribution in the US marketplace and 57 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
Ranolazine is drug used to treat angina.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
